Human platelet suspension stimulates porcine retinal glial proliferation and migration in vitro

Investigative Ophthalmology and Visual Science

Volumn 41, Issue 2, 2000, Pages 601-609

  Castelnovo, Laurent ^a   Dosquet, Christine ^b   Gaudric, Alain ^c   Sahel, José ^a   Hicks, David ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENISTEIN; GROWTH FACTOR; THYMIDINE; TYROSINE KINASE RECEPTOR;

ADJUVANT THERAPY; ANIMAL CELL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; RETINA MACULA HOLE; THROMBOCYTE;

ANIMALS; BLOOD PLATELETS; CELL DIVISION; CELL MOVEMENT; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENISTEIN; GROWTH SUBSTANCES; HUMANS; NEUROGLIA; RECEPTOR PROTEIN-TYROSINE KINASES; RETINA; SWINE;

EID: 0033976357     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Gass JD. Stereoscopic Atlas of Macular Disease: Diagnosis and Treatment. 3rd ed St. Louis: CV Mosby; 1987.
2. Schocket SS, Lakhanpal V, Miao XP, et al. Laser treatment of macular holes. Ophthalmology. 1988;95:574-582.
3. Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes. A pilot study. Arch Ophthalmol. 1991;109:654-659.
4. Wendel RT, Patel AC, Kelly NE, et al. Vitreous surgery for macular holes. Ophthalmology. 1993;100:1671-1676.
5. Freeman WR, Azen SP, Kim JW, et al. Vitrectomy for the treatment of full thickness stage 3 or 4 macular holes. Results of a multicentered randomized clinical trial. The vitrectomy for treatment of macular hole study group. Arch Ophthalmol. 1997;115:11-21.
6. Paques M, Chastang C, Mathis A, et al. Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double-masked, randomized trial. Ophthalmology. 1999;106:932-938.
7. Glaser BM, Michels RG, Kuppermann BD, et al. Tranforming growth factor β2 for the treatment of full-thickness macular hole: a prospective randomized study. Ophthalmology. 1992;99:1162-1173.
8. Lansing MB, Glaser BM, Liss H, et al. The effect of pars planar vitrectomy and transforming growth factor beta 2 without epiretinal membrane peeling on full-thickness macular holes. Ophthalmology. 1993;100:868-872.
9. Thompson JT, Smiddy WE, Williams GA, et al. Comparison of recombinant transforming growth factor beta-2 and placebo as an adjunctive agent for macular hole surgery. Ophthalmology. 1998; 105:700-706.
10. Liggett PE, Skolik SA, Horio B, et al. Human autologous serum for the treatment of full-thickness macular holes. Ophthalmology. 1995;102:1071-1076.
11. Gaudric A, Massin P, Paques M, et al. Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol. 1995;233:549-554.
12. Gaudric A, Paques M, Massin P, Santiago P-Y, Dosquet C. Use of autologous platelet concentrate in macular hole surgery: report of 77 cases. In: Weidemann P, Kohen L, eds. Macular and Retinal Diseases. Vol. 29. Basel, Switzerland: Karger; 1997:30-35.
13. Korobelnik JF, Hannouche D, Belayachi N, et al. Autologous platelet concentrate as an adjunct in macular hole healing. Ophthalmology. 1996;103:590-594.
14. Faude F, Edel E, Dannhauer M, et al. Autologous thrombocyte administration in treatment of idiopathic macular foramen. Ophthalmologe. 1997;94:877-881.
15. Minihan M, Cleary PE. Autologous platelet concentrate in the surgical management of macular holes. In: Weidemann P, Kohen L, eds. Macular and Retinal Diseases. Vol. 29. Basel, Switzerland: Karger; 1997;29:36-43.
16. Minihan M, Goggin M, Cleary PE. Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor β2. Br J Ophthalmol. 1997;81:1073-1079.
17. Funata M, Wendel RT, De La Cruz Z, et al. Clinicopathologic study of bilateral macular holes treated with pars planar vitrectomy and gas tamponade. Retina. 1992;12:289-298.
18. Madreperla SA, Greer L, Geiger L, et al. Clinicopathologic correlation of a macular hole treated by cortical vitreous peeling and gas tamponade. Ophthalmology. 1994;101:682-686.
19. Smiddy WE, Glaser BM, Green WR, et al. Transforming growth factor beta 2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes. Retina. 1993;13:296-301.
20. Christmas NJ, Skolik SA, Howard MA, et al. Treatment of retinal breaks with autologous serum in an experimental model. Ophthalmology. 1995;102:263-271.
21. De Juan E, Dickson JS, Hjelmeland L. Serum is chemotactic for retinal-derived glial cells. Arch Ophthalmol. 1988;106:986-990.
22. Guidry C. Isolation and characterization of porcine Müller cells. Myofibroblastic dedifferentiation in culture. Invest Ophthalmol Vis Sci. 1996;37:740-752.
23. Dosquet C, Benbunan M, Deschamps JF, et al. Autologous platelet suspension (APS) as adjuvant therapy for the treatment of full-thickness macular holes (Abstract). Blood. 1997;90(suppl):165a.
24. Nakanishi O, Shibasaki F, Hidaka M, et al. Phospholipase C-γ1 associates with viral and cellular src kinases. J Biol Chem. 1993; 268:10754-10759.
25. Maher PA. Inhibition of the tyrosine kinase activity of the fibroblast growth factor receptor by the methyltransferase inhibitor 5′-methylthioadenosine. J Biol Chem. 1993;268:4244-4249.
26. Secrist JP, Sehgal I, Powis G, Abraham T. Preferential inhibition of the platelet-derived growth factor receptor tyrosine kinase by staurosporine. JBiol Chem. 1990;265:20394-20400.
27. Dvir A, Milner Y, Chomsky O, et al. The inhibition of EGF-dependent proliferation of keratinocytes by tyrphostin tyrosine kinase blockers. J Cell Biol. 1991;113:857-865.
28. Harper JF. Peritz "f" test: Basic program of a robust multiple comparison test for statistical analysis of all differences among group means. Comp Biol Med. 1984;14:437-445.
29. Gregor ZJ. Surgery for idiopathic full-thickness macular holes. Eye. 1996;10:685-690.
30. Massagué J. The transforming growth factor β family. Annu Rev Cell Biol. 1990;6:597-641.
31. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin 1 is a major activator of TGF-β1 in vivo. Cell. 1998;93: 1159-1170.
32. Brown PD, Wakefield LM, Levinson AD, Sporn MB. Physicochemical activation of recombinant latent transforming growth factor βs 1, 2 and 3. Growth Factors. 1990;3:35-43.
33. Bachem MG, Reiss U, Melchior U, Se KM, Gressner AM. Transforming growth factors (TGF-α and TGF-β1) stimulates chondroitin sulfate and hyaluronate synthesis in cultured rat liver fat storing cells. FEBS Lett. 1989;257:134-137.
34. Fox GM, Schiffer SG, Rohde MF, et al. Production, biological activity and structure of recombinant basic fibroblast growth factor and an analogue with cysteine replaced by serine. J Biol Chem. 1988;263:18452-18458.
35. Gu X, Seong GJ, Lee YG, Kay EDP. Fibroblast growth factor 2 uses distinct signaling pathways for cell proliferation and cell shape changes in corneal endothelial cells. Invest Ophthalmol Vis Sci. 1996;37:2326-2334.
36. Vahlhaus C, Schulz R, Post H, Onallah R, Heusch G. No prevention of ischemic reconditioning by the protein kinase C inhibitor staurosporine in swine. Circ Res. 1996;79:407-414.
37. Cook DR, Doumit ME, Merkel RA. Transforming growth factor beta, basic fibroblast growth factor and platelet-derived growth factor BB interact to affect proliferation of clonally derived porcine satellite cells. J Cell Physiol. 1993;157:307-312.
38. Heldin C-H, Wasteson A, Westermark B. Growth of normal human glial cells in a defined medium containing platelet-derived growth factor. Proc Natl Acad Sci USA. 1980;77:6611-6615.
39. Uchihori Y, Puro DG. Mitogenic and chemotactic effects of platelet-derived growth factor on human retinal glial cells. Invest Ophthalmol Vis Sci. 1991;32:2689-2695.
40. Puro DG. Growth factors and Müller cells. Prog Ret Eye Res. 1995;15:89-101.
41. Burke JM. Cultured retinal glial cells are insensitive to platelet-derived growth factor. Exp Eye Res. 1982;35:663-669.
42. Small RK, Patel P, Watkins BA. Response of Müller cells to growth factors alters with time in culture. Glia. 1991;4:469-483.
43. Heldin C-H, Westermark B, Wasteson A. Platelet-derived growth factor: purification and partial characterization. Proc Natl Acad Sci USA. 1979;76:3722-3726.
44. Roque RS, Caldwell RB, Behzadian MA. Cultured Müller cells have high levels of epidermal growth factor receptors. Invest Ophthalmol Vis Sci. 1992;33:2587-2595.
45. Fukagawa K, Saito H, Tsubota K, et al. RANTES production in a conjunctival epithelial cell line. Cornea. 1997;16:564-570.
46. Deuel TF. Protein granule factors. In: von Bruchausen F, Walter U, eds. Handbook of Experimental Pharmacology: Platelets and their Factors. Vol. 126. Springer-Verlag, 1997:433-439.
47. Ryo R, Proffitt RT, Deuel TF. Human platelet factor 4: subcellular localization and characteristics of release from intact platelets. Thromb Res. 1980;17:629-644.
48. Baenziger NL, Brodie GN, Majerus PW. A thrombin-sensitive protein of human platelet membranes. Proc Natl Acad Sci USA. 1971;68:240-244.
49. Hynes RO. The complexity of platelet adhesion to extracellular matrices. Thromb Haemost. 1991;66:40-43.
50. Brisson C, Azorsa DO, Jennings LK, et al. Co-localization of CD9 and GPIIb-IIIa (alpha IIb beta 3 integrin) on activated platelet pseudopods and alpha-granule membranes. Histochem J. 1997;29: 153-165.
51. Tole S, Patterson PH. Distribution of CD9 in the developing and mature rat nervous system. Dev Dyn 1993;197:94-106.